Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pelthos Therapeutics (PTHS) Operating Expenses (2024 - 2025)

Pelthos Therapeutics has reported Operating Expenses over the past 2 years, most recently at $45.6 million for Q4 2025.

  • Quarterly results put Operating Expenses at $45.6 million for Q4 2025, up 605.2% from a year ago — trailing twelve months through Dec 2025 was $53.4 million (up 404.33% YoY), and the annual figure for FY2025 was $49.2 million, up 550.18%.
  • Operating Expenses for Q4 2025 was $45.6 million at Pelthos Therapeutics, up from $2.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for PTHS hit a ceiling of $45.6 million in Q4 2025 and a floor of $437000.0 in Q3 2024.